Hence, targeted combination regimens using a BCL2-inhibitor backbone have become one of the cornerstones of modern CLL management: Currently, the combination of the BCL2 inhibitor venetoclax and the CD20 antibody obinutuzumab are FDA and EMA approved as well as the all-oral combination of venetoclax with the BTK inhibitor ibrutinib (only EMA approved) for the first-line treatment of CLL. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.